Article
Immunology
Julien Lupo, Raphaele Germi, Remi Lancar, Michele Algarte-Genin, Houria Hendel-Chavez, Yassine Taoufik, Nicolas Mounier, Marialuisa Partisani, Fabrice Bonnet, Marie-Caroline Meyohas, Bruno Marchou, Anastasiia Filippova, Sophie Prevot, Dominique Costagliola, Patrice Morand, Caroline Besson
Summary: In the modern cART era, the EBV DNA load in whole blood and plasma at NHL diagnosis does not serve as prognostic markers for HIV-NHL patients.
Article
Oncology
Shuyan Yao, Zhili Jin, Lingbo He, Ruoxi Zhang, Menghan Liu, Zhengjie Hua, Zhao Wang, Yini Wang
Summary: The study showed significant differences in pathological types, clinical characteristics, and prognosis between lymphoma patients with or without LAHS. Age, platelet count, IPI, history of lymphoma, and lack of HLH remission were identified as independent risk factors for the prognosis of NHL-LAHS patients.
FRONTIERS IN ONCOLOGY
(2021)
Review
Cell Biology
Valli De Re, Ombretta Repetto, Lara Mussolin, Giulia Brisotto, Caterina Elia, Egesta Lopci, Emanuele S. G. d'Amore, Roberta Burnelli, Maurizio Mascarin
Summary: Currently-available therapies for newly-diagnosed pediatric and adolescent patients with Hodgkin lymphoma result in high survival rates, but long-term treatment-related side effects are a concern. Clinical trials have been conducted to improve the situation by abandoning adult regimens and exploring narrower-field radiotherapy and risk-adapted chemo-radiotherapy strategies. Early assessment of tumor response and the use of aggressive therapies for poor responders have also been explored. New drugs for the prevention and treatment of relapsed and refractory classical Hodgkin lymphoma have been proposed.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Article
Virology
Julien Lupo, Mansour Tsougaev, Stephane Blachier, Guillaume Chovelon, Aurelie Truffot, Corentin Leroy, Joris Giai, Olivier Epaulard, Raphaele Germi, Patrice Morand
Summary: This study compared the performance of two immunoassays for detecting serological markers of EBV infection. The results showed a high agreement between the two methods, but differences were found in sensitivity and detection rates for early primary infection and past infection.
JOURNAL OF MEDICAL VIROLOGY
(2023)
Article
Oncology
O. Jimenez, S. Colli, M. Garcia Lombardi, M. V. Preciado, E. De Matteo, P. Chabay
Summary: The presence of EBV does not influence PD1 and PDL1 expression in pediatric cHL, but in EBV-related cases, a higher number of PDL1+ cells were detected in the microenvironment.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2021)
Review
Oncology
Jianyu Hu, Xue Zhang, Huan Tao, Yongqian Jia
Summary: This study aimed to evaluate the prognostic significance of Epstein-Barr virus (EBV) infection in Hodgkin lymphoma (HL) patients. The results showed that EBV positivity was associated with poorer overall survival (OS) and disease-specific survival (DSS) in HL patients. However, the presence of EBV in HL did not affect failure-free survival, progression-free survival, or event-free survival. Subgroup analyses also revealed that EBV positivity was associated with a poorer prognosis in elderly patients, while children and adolescents with EBV-positive HL tended to have a better prognosis, although not statistically significant.
FRONTIERS IN ONCOLOGY
(2022)
Review
Biotechnology & Applied Microbiology
Selma Addou, Clementine Sarkozy, Julien Lazarovici, Stephane Champiat, Aspasia Stamatoullas, Fabrice Jardin, Vincent Ribrag, Aurelien Marabelle, Jean-Marie Michot
Summary: Classical Hodgkin lymphoma is a neoplastic hematological disease with a high cure rate in early-stage patients but 15% of patients require new treatment strategies. Some documented cases show cancer remission following viral infections, leading researchers to investigate oncolytic viruses for treating Hodgkin lymphoma. Modern viral technologies and understanding of viruses' relationship with cancer could accelerate the development of effective viral oncolytic therapies.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2021)
Article
Oncology
Kelly J. Yu, Wan-Lun Hsu, Chun-Ju Chiang, Tseng-Cheng Chen, Zhiwei Liu, Pei-Jen Lou, Scott Diehl, Alisa M. Goldstein, Chien-Jen Chen, Cheng-Ping Wang, Allan Hildesheim
Summary: This study reassessed familial aggregation of cancer in high-risk Taiwanese multiplex families with NPC cases and found evidence of NPC coaggregation within families, but not a broader familial syndrome involving NPC and other tumors. The study also observed elevated rates of secondary cancers among NPC cases, mostly head and neck and hematopoietic cancers, suggesting radiation treatment effects on subsequent cancer risk.
Article
Virology
Ozgur Appak, Muge H. Ozkaratas, Ayca A. Sayiner
Summary: This study compared the performance of four different assays for detecting EBV infection markers, with Vidas showing excellent performance for all EBV profiles and Immulite and Vidas being most accurate in detecting VCA IgM. Overall, the evaluated assays had comparable performance.
JOURNAL OF MEDICAL VIROLOGY
(2021)
Article
Oncology
Xia Zhao, Yushuo Ma, Haiyan Bian, Zhihe Liu
Summary: This study systematically explored the clinical significance of EBV infection, expression of CD20, and their relationship in NSCHL. The results showed that CD20 was strongly expressed in NSCHL patients who had been infected with EBV, and CD20 positivity was found to be an independent risk factor for NSCHL patients' survival.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Magdalena M. Brune, Darius Juskevicius, Jasmin Haslbauer, Stefan Dirnhofer, Alexandar Tzankov
Summary: Hodgkin lymphoma (HL) consists mainly of reactive cells with only a few cancer cells, making high-throughput molecular investigation challenging for a long time. Recently developed methods have allowed for the analysis of genetic alterations in Hodgkin and Reed-Sternberg (HRS) or lymphocyte predominant (LP) cells, which impact immune evasion, proliferation, and evasion of programmed cell death. Understanding these molecular mechanisms is crucial for prognosis, prediction, and improving therapy, especially for patients with recurrent or treatment-resistant disease.
Article
Pathology
Fei Fei, Kala Gnanasekaran Kiruthiga, Sheren Younes, Yasodha Natkunam
Summary: This study characterizes the clinicopathologic features of Epstein-Barr virus (EBV)-positive nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) at a single institution. The study found that EBV-positive NLPHL is rare and diagnostically challenging due to atypical immunophenotypic features.
Article
Oncology
Tharcisse Mpunga, Gary M. Clifford, Elizabeth A. Morgan, Danny A. Jr Jr Milner, Catherine de Martel, Cyprien Munyanshongore, Gaspard Muvugabigwi, Jean-Damien Combes
Summary: The study found that the prevalence of EBV in Hodgkin lymphoma (HL) diagnosed in the Butaro Cancer Center of Excellence in Rwanda is 54%, with detection in all classical subtypes. In non-Hodgkin lymphoma (NHL), the EBV prevalence is 9%, with Burkitt lymphoma in B-cell NHL having the highest detection rate of EBV.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Oncology
Ziyuan Shen, Lingling Hu, Mingkang Yao, Chenlu He, Qinhua Liu, Fei Wang, Weiying Gu, Ying Wang, Manyu Dong, Taigang Zhu, Ting Yin, Fei Li, Yingliang Jin, Shuiping Huang, Hao Zhang, Wei Sang
Summary: A retrospective multicenter study of 454 lymphoma patients found that elevated EBV DNA load can affect the prognosis of NKTL, FL, and DLBCL. The integration of EBER status and EBV DNA can differentiate the prognosis of HL patients.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Biochemistry & Molecular Biology
Seifegebriel Teshome, Elshafa Hassan Ahmed, Kidist Zealiyas, Abdulaziz Abubeker, Fisihatsion Tadesse, Christoph Weigel, Robert A. Baiocchi, Tamrat Abebe
Summary: This study investigated the genetic variation of EBV in lymphoma patients in Ethiopia. The results showed a higher distribution of EBV genotype 1 in these patients, and a significant association between age groups and EBV genotypes was observed.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Yuehan Zhang, Tim Waterboer, Michael Pawlita, Elizabeth Sugar, Howard Minkoff, Ross D. Cranston, Dorothy Wiley, Robert Burk, Susheel Reddy, Joseph Margolick, Howard Strickler, Kathleen Weber, Maura Gillison, Gypsyamber D'Souza
CANCER EPIDEMIOLOGY
(2016)
Article
Oncology
Anala Gossai, Tim Waterboer, Heather H. Nelson, Jennifer A. Doherty, Angelika Michel, Martina Willhauck-Fleckenstein, Shohreh F. Farzan, Brock C. Christensen, Anne G. Hoen, Ann E. Perry, Michael Pawlita, Margaret R. Karagas
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
(2016)
Review
Oncology
Paolo Boscolo-Rizzo, Michael Pawlita, Dana Holzinger
CANCER TREATMENT REVIEWS
(2016)
Article
Gastroenterology & Hepatology
Janett Fischer, Alexander N. R. Weber, Stephan Boehm, Sabine Dickhoefer, Souhayla El Maadidi, Danilo Deichsel, Viola Knop, Hartwig Klinker, Bernd Moeller, Jens Rasenack, Lisa Wang, Manu Sharma, Holger Hinrichsen, Ulrich Spengler, Peter Buggisch, Christoph Sarrazin, Michael Pawlita, Tim Waterboer, Manfred Wiese, Elsbeth Probst-Mueller, Raffaele Malinverni, Pierre-Yves Bochud, Clair M. Gardiner, Cliona O'Farrelly, Thomas Berg
Article
Oncology
Tianyi Wang, Hui Cai, Shizuka Sasazuki, Shoichiro Tsugane, Wei Zheng, Eo Rin Cho, Sun Ha Jee, Angelika Michel, Michael Pawlita, Yong-Bing Xiang, Yu-Tang Gao, Xiao-Ou Shu, Wei-Cheng You, Meira Epplein
INTERNATIONAL JOURNAL OF CANCER
(2017)
Article
Oncology
Anala Gossai, Tim Waterboer, Anne G. Hoen, Shohreh F. Farzan, Heather H. Nelson, Angelika Michel, Martina Willhauck-Fleckenstein, Brock C. Christensen, Ann E. Perry, Michael Pawlita, Margaret R. Karagas
Article
Oncology
Dana Holzinger, Gunnar Wichmann, Lorena Baboci, Angelika Michel, Daniela Hoefler, Manuel Wiesenfarth, Lea Schroeder, Paolo Boscolo-Rizzo, Christel Herold-Mende, Gerhard Dyckhoff, Andreas Boehm, Annarosa Del Mistro, Franz X. Bosch, Andreas Dietz, Michael Pawlita, Tim Waterboer
INTERNATIONAL JOURNAL OF CANCER
(2017)
Letter
Dermatology
Daniele Viarisio, Karin Mueller-Decker, Jessica C. Hassel, Jean-Claude Alvarez, Christa Flechtenmacher, Michael Pawlita, Lutz Gissmann, Massimo Tommasino
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2017)
Article
Pathology
Gordana Halec, Laia Alemany, Beatriz Quiros, Omar Clavero, Daniela Hofler, Maria Alejo, Wim Quint, Michael Pawlita, Francesc X. Bosch, Silvia de Sanjose
Article
Multidisciplinary Sciences
Pia Marie Albano, Dana Holzinger, Christianne Salvador, Jose Orosa, Sheryl Racelis, Modesty Leano, Danilo Sanchez, Lara Mae Angeles, Gordana Halec, Markus Schmitt, John Donnie Ramos, Michael Pawlita
Article
Microbiology
Domenico Mattoscio, Chiara Casadio, Claudia Miccolo, Fausto Maffini, Andrea Raimondi, Carlo Tacchetti, Tarik Gheit, Marta Tagliabue, Viviana E. Galimberti, Francesca De Lorenzi, Michael Pawlita, Fausto Chiesa, Mohssen Ansarin, Massimo Tommasino, Susanna Chiocca
Article
Oncology
Gary M. Clifford, Tim Waterboer, Bolormaa Dondog, You Lin Qiao, Dimitri Kordzaia, Doudja Hammouda, Namory Keita, Nahid Khodakarami, Syed Ahsan Raza, Ang Tshering Sherpa, Witold Zatonski, Michael Pawlita, Martyn Plummer, Silvia Franceschi
INFECTIOUS AGENTS AND CANCER
(2017)
Article
Oncology
Heather H. Nelson, Michael Pawlita, Dominique S. Michaud, Michael McClean, Scott M. Langevin, Melissa N. Eliot, Karl T. Kelsey
Article
Multidisciplinary Sciences
Valentina Lupato, Dana Holzinger, Daniela Hofler, Anna Menegaldo, Paolo Giorgi Rossi, Annarosa Del Mistro, Maria Cristina Da Mosto, Michael Pawlita, Paolo Boscolo-Rizzo
Article
Virology
Daniel C. Beachler, Tim Waterboer, Christine M. Pierce Campbell, Donna J. Ingles, Krystle A. Lang Kuhs, Alan G. Nyitray, Allan Hildesheim, Michael Pawlita, Aimee R. Kreimer, Anna R. Giuliano
PAPILLOMAVIRUS RESEARCH
(2016)
Article
Oncology
Yuxin Liu, Swati Bhardwaj, Keith Sigel, John Winters, Joseph Terlizzi, Michael M. Gaisa
Summary: This study investigated the prevalence and severity of anal HPV disease among MSM LWH under the age of 35, finding a high prevalence of HPV infection and precancer but no cases of invasive anal cancer. This supports the adoption of age-based anal cancer screening for this population.
INTERNATIONAL JOURNAL OF CANCER
(2024)
Correction
Oncology
J. Gu, S. Xie, S. Wang
INTERNATIONAL JOURNAL OF CANCER
(2024)